$500K for Alzheimer’s Diagnostic
NeuroQuest has received $500,000 for a novel blood test for early detection of Alzheimer’s and other forms of dementia. The funding round was led by the InterTech Group in South Carolina and the Maryland/Israel Trendlines Fund and will enable a clinical trial at four US medical centers. Its first human trials in Israel showed NeuroQuest’s test — which is based on 20 years of research by Prof. Michal Schwartz of the Weizmann Institute of Science — to be 87 percent accurate with an 85% specificity rate in detecting Alzheimer’s and ALS, two common neurodegenerative diseases. NeuroQuest hopes to provide the same early-warning capability to people in the first stages of Alzheimer’s, ALS, Parkinson’s and other progressive neurodegenerative diseases.